The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.
 
Tamim Niazi
Honoraria - Abbvie; Astellas Pharma; Bayer; Janssen Oncology; Sanofi; Tersera
Consulting or Advisory Role - Abbvie; Bayer; Janssen Oncology; Sanofi; Tersera
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Sanofi (Inst); Tersera (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Sanofi; Tersera
 
Scott Williams
Consulting or Advisory Role - Amgen; Janssen (Inst)
Travel, Accommodations, Expenses - Astellas Pharma
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
 
Martin R. Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Tilray (Inst)
Travel, Accommodations, Expenses - Medivation/Pfizer
 
Andrew James Martin
No Relationships to Disclose
 
Wendy Hague
No Relationships to Disclose
 
Karen Bracken
Research Funding - Bayer Health; Bayer Health
 
Margot Gorzeman
No Relationships to Disclose
 
Felicia Roncolato
No Relationships to Disclose
 
Sonia Yip
No Relationships to Disclose
 
Lisa Horvath
Employment - Connected Medical Solutions (I)
Leadership - Connected Medical Solutions (I)
Stock and Other Ownership Interests - Connected Medical Solutions (I)
Consulting or Advisory Role - Imagion Biosystems
Research Funding - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma; Janssen-Cilag; Pfizer
 
Shomik Sengupta
Consulting or Advisory Role - Janssen (Inst)
Speakers' Bureau - Ipsen (Inst); Merck Sharp & Dohme (Inst); Mundipharma (Inst)
Research Funding - AstraZeneca (Inst); MSD (Inst)
 
Simon Hughes
Honoraria - Astellas Pharma; Bayer; Janssen Oncology
Consulting or Advisory Role - Janssen Oncology
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen Oncology
(OPTIONAL) Uncompensated Relationships - AstraZeneca (Inst); Merck (Inst); MSD (Inst)
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
James WF Catto
Honoraria - Abbott Laboratories
Speakers' Bureau - ASCO
Travel, Accommodations, Expenses - European Association of Urology
 
Neha Vapiwala
Consulting or Advisory Role - Magellan Health
 
Wendy R. Parulekar
Consulting or Advisory Role - Pfizer
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination